Purchase Order 75N91018P00515

<p>The National Cancer Institute awarded a purchase order to Genus Biosystems Inc. for $57,564.00 on September 17, 2018. The order, which carried no set-aside designation, covers exploration of gene expression and microRNA expression changes in tumors exposed to radiation, with and without specified treatment modalities. Work is performed in Northbrook, Illinois. The order is firm fixed price and carries an ultimate completion date of September 16, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genus Biosystems Inc. valued at $55,879.20 on March 15, 2019, for identifying radiation-induced RNA markers in lung and liver tissue samples from whole-body irradiation studies. Work is performed in Northbrook, Illinois. The order carries a firm fixed price and was completed by August 15, 2019. The procurement originated from a special notice posted February 14, 2019, with a response deadline of February 28, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Genus Biosystems Inc. valued at $38,179.20 on September 19, 2019. No set-aside was used. Work is performed in Northbrook, Illinois. The order is firm fixed price with an ultimate completion date of January 19, 2020. The solicitation was posted August 22, 2019 as a Special Notice with a due date of August 28, 2019.</p>

This firm fixed price purchase order, awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute, is for $37,785.60 in mRNA and microRNA microarray profiling services to support the prediction of radiation therapy outcomes. The prime contractor is Genus Biosystems Inc., located in Northbrook, Illinois, and no set-aside designation was applied to this procurement. The contract completion date is August 19, 2024, suggesting the National Cancer...

<p>The National Cancer Institute issued a purchase order to Genus Biosystems Inc. valued at $14,287.68 on September 15, 2017, with completion by October 31, 2017. Work is performed in Northbrook, Illinois. No set-aside applies. The order procures laboratory testing services in genomics and transcriptomics to support cancer research.</p>

<p>The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a firm fixed-price purchase order to Genus Biosystems Inc., a for-profit organization, for $23,520.00 to provide lab testing services. The contract has a completion date of November 1, 2024 and was awarded on May 1, 2024. The place of performance is Northbrook, IL 60062, USA. This contract award is not associated with any set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Gryphon Scientific, LLC for $63,300 on September 23, 2019, to identify radiation-injury markers predicting organ damage and survival following whole-body irradiation in mouse and minipig models. Work is performed in Beverly, Massachusetts under a firm fixed-price structure, with completion targeted for November 22, 2019. The order originated from a Special Notice posted August 19, 2019 with a due date of August 26, 2019.</p>

<p>The National Cancer Institute issued a purchase order to Gryphon Scientific, LLC for $24,100 on April 3, 2019, to identify biomarker signatures in the minipig model for different radiation doses and time points and annotate unannotated minipig probes. Work is performed in Bethesda, Maryland. The contract carries fixed-price pricing with economic price adjustment and has an ultimate completion date of April 2, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Genepria Consulting Inc. for $15,000 on August 26, 2019, with final completion on September 1, 2020, for support services related to an imaging system. Performance location is Bethesda, Maryland. The order carries firm fixed price terms and no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Nexome Genomics Inc. for $14,575.00 on July 2, 2018. Performance is based in Bethesda, Maryland. The order carries a firm fixed price structure and a completion date of August 2, 2018. No set-aside category applies.</p>